By Will Feuer


Pfizer Inc. is developing new packaging for its Nurtec ODT prescription drug after the U.S. Consumer Product Safety Commission found the packaging wasn't child-resistant and issued a recall alert.

The commission earlier Thursday issued a recall alert for the migraine medication, urging consumers to secure the product out of sight and reach of children and to contact Pfizer for a free child-resistant pouch to store the product. Pfizer said customers don't need to return the drug.

"Patients should rest assured that there are no quality or safety issues nor health risks when they take the medicine as prescribed for its approved use," Pfizer said.

No incidents or injuries tied to the product have been reported, the commission said.

Nurtec ODT is manufactured by Biohaven Pharmaceutical Holding Co. Ltd., which Pfizer bought in October last year. The commission said its alert applies to 75-milligram, orally disintegrating Nurtec ODT tablets that are sold in cartons containing one blister card of 8 tablets.

The commission said the packaging issue affects about 4.2 million units of Nurtec ODT and likely an estimated 300,000 more units currently out in the marketplace.

As an interim measure, Pfizer has instructed pharmacists to place the non-child-resistant blister in a child-resistant vial prior to dispensing the medication to patients.


Write to Will Feuer at


(END) Dow Jones Newswires

March 16, 2023 13:33 ET (17:33 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
過去 株価チャート
から 5 2023 まで 6 2023 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 6 2022 まで 6 2023 Pfizerのチャートをもっと見るにはこちらをクリック